Analyst Consensus ?
ConsensusHold39 ratings
Bullish1948.7%
Neutral2051.3%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Healthpeak Properties, Inc. · DOC · FY2024 Q4 · Calendar Q1 2025
Healthpeak Maintains 2025 Guidance as Investment Plan Expands
The supplied analysis supports a constructive but execution-dependent view: merger synergies, internalization, leasing, pre-leased development, and distressed life-science opportunities may support results, while capex, leverage, interest expense, and execution risks constrain the case.
Reported After market closeNYSEReal Estate
$12.96B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $0.05
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $691.8M
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-1.6%
Event window
SPY move
+0.7%
Same window
Abnormal move
-2.2%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+1.8%
Up to 20 sessions
DOCSPY benchmark
Ask FN2 about DOC FY2024 Q4
Transcript, numbers and history already loaded
What drove DOC's -1.6% move after FY2024 Q4 earnings?What changed in DOC's guidance and outlook in FY2024 Q4?Give me the bull and bear case for DOC after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, guidance sentiment shifted from raised to maintained. The current analysis places greater emphasis on a $500 million 2025 investment plan, $600 million of development and redevelopment spending, further property-management internalization, and loan structures tied to strategic asset acquisition.
Guidance delta
Current analysis describes 2025 guidance as maintained; prior-quarter analysis described guidance sentiment as raised.
Key takeaways
- The current analysis describes strong FY2024 performance and same-store growth across segments.
- Management highlighted a $500 million 2025 investment plan spanning life-science loans, acquisitions, and development.
- A $600 million development and redevelopment run-rate raises the importance of capex timing and execution.
- Property-management internalization and merger synergies remain central to the operating plan.
- Senior-housing CCRC sales and pre-leased development projects were identified as growth supports.
Management priorities
- Deploy $500 million in 2025 across life-science loans, acquisitions, and development projects.
- Allocate $600 million to development and redevelopment spending.
- Internalize approximately 8 million square feet of property management.
- Maintain monthly dividends and a conservative AFFO payout ratio.
- Expand loan-to-cost and purchase-option structures for strategic asset acquisition.
Follow DOC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$18.98Current
$15Low
$20.92Average
$28High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 14, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | In Line | In Line | Maintain | Sep 21, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 31, 2026 |
| Baird | Outperform | Outperform | Maintain | Aug 13, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 11, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 10, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Aug 6, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 15, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 6, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jun 24, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jun 15, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jun 11, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | May 27, 2026 |
| Argus Research | Hold | Buy | Downgrade | Feb 5, 2026 |
| Jefferies | Hold | Buy | Downgrade | Dec 16, 2025 |
| Raymond James | Outperform | Market Perform | Upgrade | Sep 15, 2025 |
| Deutsche Bank | Hold | Buy | Downgrade | Aug 20, 2025 |
| Wedbush | Outperform | Outperform | Maintain | Apr 28, 2025 |
| B of A Securities | Buy | Underperform | Upgrade | Apr 1, 2024 |
| Keybanc | Overweight | Downgrade | Jan 5, 2024 | |
| Compass Point | Buy | Buy | Maintain | Jan 2, 2024 |
| Truist Securities | Hold | Hold | Maintain | Dec 22, 2023 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Sep 28, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 4, 2022 |
| Berenberg | Buy | Hold | Upgrade | May 20, 2021 |
| B. Riley Securities | Buy | Buy | Maintain | May 7, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Apr 22, 2020 |
| BTIG Research | Neutral | Buy | Downgrade | Mar 16, 2020 |
| BTIG | Neutral | Buy | Downgrade | Mar 15, 2020 |
| B. Riley FBR | Buy | Buy | Maintain | Feb 27, 2020 |
| Stifel Nicolaus | Buy | Hold | Upgrade | Nov 26, 2019 |
| Stifel | Buy | Hold | Upgrade | Nov 25, 2019 |
| Capital One Financial | Equal Weight | Overweight | Downgrade | May 2, 2019 |
| Capital One | Equal Weight | Overweight | Downgrade | May 1, 2019 |
| Bank of America | Buy | Buy | Maintain | Mar 8, 2018 |
| Hilliard Lyons | Buy | Long Term Buy | Maintain | Nov 5, 2017 |
| JMP Securities | Market Perform | Outperform | Downgrade | Jun 21, 2016 |
| FBR Capital | Outperform | Outperform | Maintain | Feb 29, 2016 |
| Wunderlich | Buy | Buy | Maintain | May 21, 2014 |
| Wunderlich Securities | Buy | Buy | Maintain | May 20, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $18.98. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Analyst unavailable | $21 | $20.37 | +10.6% | Sep 15, 2026 |
| Barclays | Analyst unavailable | $24 | $20.96 | +26.4% | Aug 31, 2026 |
| Cantor Fitzgerald | Richard Anderson | $23 | $21.52 | +21.2% | Aug 6, 2026 |
| Wells Fargo | Analyst unavailable | $22 | $21.66 | +15.9% | Jul 15, 2026 |
| Barclays | Analyst unavailable | $23 | $21.75 | +21.2% | Jul 7, 2026 |
| Mizuho Securities | Vikram Malhotra | $24 | $21.86 | +26.4% | Jul 6, 2026 |
| BMO Capital | Analyst unavailable | $24 | $20.69 | +26.4% | Jun 15, 2026 |
| Morgan Stanley | Ronald Kamdem | $22 | $20.76 | +15.9% | Jun 11, 2026 |
| Scotiabank | Analyst unavailable | $21 | $20.06 | +10.6% | May 27, 2026 |
| Morgan Stanley | Ronald Kamdem | $20 | $19.7 | +5.4% | May 22, 2026 |
| UBS | Analyst unavailable | $19 | $19.78 | +0.1% | May 13, 2026 |
| Morgan Stanley | Analyst unavailable | $18 | $15.83 | -5.2% | Apr 28, 2026 |
| UBS | Analyst unavailable | $17 | $17.37 | -10.4% | Apr 20, 2026 |
| Wells Fargo | John Kilichowski | $18 | $16.92 | -5.2% | Feb 3, 2026 |
| Goldman Sachs | Analyst unavailable | $17 | $17.04 | -10.4% | Jan 9, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $17 | $16.16 | -10.4% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $17 | $16.66 | -10.4% | Dec 15, 2025 |
| Evercore ISI | Analyst unavailable | $21 | $16.8 | +10.6% | Dec 15, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $20 | $19.15 | +5.4% | Oct 1, 2025 |
| Evercore ISI | Analyst unavailable | $22 | $18.08 | +15.9% | Sep 15, 2025 |
| Raymond James | Jonathan Hughes | $20 | $18.25 | +5.4% | Sep 15, 2025 |
| Morgan Stanley | Analyst unavailable | $21 | $17.75 | +10.6% | Aug 22, 2025 |
| Robert W. Baird | Analyst unavailable | $21 | $17.22 | +10.6% | Jul 30, 2025 |
| Deutsche Bank | Omotayo Okusanya | $28 | $22.64 | +47.5% | Oct 21, 2024 |
| Citigroup | Nick Joseph | $22 | $21.89 | +15.9% | Aug 21, 2024 |
| Robert W. Baird | Wesley Golladay | $24 | $21.85 | +26.4% | Jul 30, 2024 |
| RBC Capital | Michael Carroll | $25 | $21.85 | +31.7% | Jul 30, 2024 |
| Wedbush | Richard Anderson | $22 | $19.17 | +15.9% | May 3, 2024 |
| RBC Capital | Michael Carroll | $22 | $19.34 | +15.9% | Apr 10, 2024 |
| Robert W. Baird | Analyst unavailable | $22 | $18.31 | +15.9% | Mar 27, 2024 |
| Wells Fargo | Connor Siversky | $19 | $17.54 | +0.1% | Mar 25, 2024 |
| Credit Suisse | Omotayo Okusanya | $15 | $14.64 | -21.0% | Aug 1, 2023 |
| Morgan Stanley | Analyst unavailable | $16.5 | $16.95 | -13.1% | Aug 31, 2022 |
| Morgan Stanley | Analyst unavailable | $16 | $16.76 | -15.7% | Jul 15, 2022 |
| Truist Financial | Analyst unavailable | $17 | $16.58 | -10.4% | Jul 11, 2022 |
| Jefferies | Analyst unavailable | $20 | $17.58 | +5.4% | Jun 30, 2022 |
| Morgan Stanley | Analyst unavailable | $17.5 | $18.55 | -7.8% | Jun 1, 2022 |
| Barclays | Analyst unavailable | $20 | $17.58 | +5.4% | Apr 26, 2022 |
| Truist Financial | Michael R Lewis | $19 | $17.26 | +0.1% | May 6, 2021 |
Track every rating change on DOC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationHealthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
Historical context
All DOC earningsLatest beats and misses
Who reports nextBeat on EPS
Get the DOC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-20T00:03:20.673815+00:00
- Polygon adjusted daily market bars · 2026-10-12T21:10:43.685909+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-12T21:10:43.682964+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-12. For educational purposes only; not investment advice.